104 related articles for article (PubMed ID: 9802061)
1. A lymphokine-activated killer (LAK)-resistant cell line, and low expression of adhesion molecules LFA-3 and VCAM-1 on its cell surface.
Komatsu F; Kajiwara M
Oncol Res; 1998; 10(5):263-9. PubMed ID: 9802061
[TBL] [Abstract][Full Text] [Related]
2. Relation of natural killer cell line NK-92-mediated cytolysis (NK-92-lysis) with the surface markers of major histocompatibility complex class I antigens, adhesion molecules, and Fas of target cells.
Komatsu F; Kajiwara M
Oncol Res; 1998; 10(10):483-9. PubMed ID: 10338151
[TBL] [Abstract][Full Text] [Related]
3. Role of LFA-3, ICAM-1, and MHC class I on the sensitivity of human tumor cells to LAK cells.
Gwin JL; Gercel-Taylor C; Taylor DD; Eisenberg B
J Surg Res; 1996 Jan; 60(1):129-36. PubMed ID: 8592403
[TBL] [Abstract][Full Text] [Related]
4. Induction of intercellular adhesion molecule 1 on small cell lung carcinoma cell lines by gamma-interferon enhances spontaneous and bispecific anti-CD3 x antitumor antibody-directed lymphokine activated killer cell cytotoxicity.
Azuma A; Yagita H; Matsuda H; Okumura K; Niitani H
Cancer Res; 1992 Sep; 52(18):4890-4. PubMed ID: 1381273
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells.
Altomonte M; Gloghini A; Bertola G; Gasparollo A; Carbone A; Ferrone S; Maio M
Cancer Res; 1993 Jul; 53(14):3343-8. PubMed ID: 7686816
[TBL] [Abstract][Full Text] [Related]
6. CD18/CD54(+CD102), CD2/CD58 pathway-independent killing of lymphokine-activated killer (LAK) cells against glioblastoma cell lines T98G and U373MG.
Komatsu F; Kajiwara M
Oncol Res; 2000; 12(1):17-24. PubMed ID: 11061342
[TBL] [Abstract][Full Text] [Related]
7. Different susceptibility of cervical keratinocytes containing human papillomavirus to cell-mediated cytotoxicity.
Wu R; Coleman N; Stanley M
Chin Med J (Engl); 1996 Nov; 109(11):854-8. PubMed ID: 9275369
[TBL] [Abstract][Full Text] [Related]
8. [LAK sensitivity of human pancreas carcinoma cell lines].
Sugiura H
Hokkaido Igaku Zasshi; 1993 Nov; 68(6):921-34. PubMed ID: 7906667
[TBL] [Abstract][Full Text] [Related]
9. Properties of target molecule of murine lymphokine-activated killer (LAK) cells and the clones.
Hashimoto Y; Kato K; Sato N; Yagi H; Yagita H; Nishimura T
Princess Takamatsu Symp; 1988; 19():315-22. PubMed ID: 3077625
[TBL] [Abstract][Full Text] [Related]
10. Effect of human interleukin 3 on the susceptibility of fresh leukemia cells to interleukin-2-induced lymphokine activated killing activity.
Cesano A; Lista P; Bellone G; Geuna M; Brizzi MF; Rossi PR; Pegoraro L; Oberholtzer E; Matera L
Leukemia; 1992 Jun; 6(6):567-73. PubMed ID: 1376379
[TBL] [Abstract][Full Text] [Related]
11. Role of adhesion molecules in lymphokine-activated killer cell killing of bladder cancer cells: further evidence for a third ligand for leucocyte function-associated antigen-1.
Jackson AM; Alexandrov AB; Prescott S; James K; Chisholm GD
Immunology; 1992 Jun; 76(2):286-91. PubMed ID: 1353063
[TBL] [Abstract][Full Text] [Related]
12. Retaliation against tumor cells showing aberrant HLA expression using lymphokine activated killer-derived T cells.
Falk CS; Noessner E; Weiss EH; Schendel DJ
Cancer Res; 2002 Jan; 62(2):480-7. PubMed ID: 11809699
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of human T-lymphotropic virus type-1 (HTLV-1)-infected cell line MT-2, which is not killed by a natural killer cell line NK-92 but is killed by lymphokine-activated killer cells.
Komatsu F; Yoshida S
Oncol Res; 1999; 11(5):213-8. PubMed ID: 10608615
[TBL] [Abstract][Full Text] [Related]
14. Reduction of LAK-sensitivity and changes in antigen expression on hepatoma cells by sodium butyrate.
Tada S; Saito H; Ebinuma H; Atsukawa K; Masuda T; Tsunematsu S; Morizane T; Ishii H
Cancer Biochem Biophys; 1996 Apr; 15(3):177-86. PubMed ID: 8937741
[TBL] [Abstract][Full Text] [Related]
15. Cancer cell cycle and adoptive immunotherapy using lymphokine-activated killer cells.
Ejiri Y; Ohara M; Suzuki T; Kasukawa R
Fukushima J Med Sci; 1997 Dec; 43(2):61-73. PubMed ID: 9640842
[TBL] [Abstract][Full Text] [Related]
16. The role of N-linked carbohydrate residues in lymphokine-activated killer cell-mediated cytolysis.
Mehta BA; Collard HR; Negrin RS
Cell Immunol; 1994 Apr; 155(1):95-110. PubMed ID: 7909499
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of LFA-3, Fas and MHC Class I on Ad5- and Ad12-transformed human cells and their susceptibility to lymphokine-activated killer (LAK) cells.
Bottley G; Cook GP; Meade JL; Holt JR; Hoeben RC; Blair GE
Virology; 2005 Aug; 338(2):297-308. PubMed ID: 15963548
[TBL] [Abstract][Full Text] [Related]
18. Correlation of class I MHC antigen levels on some human tumor cell lines with susceptibility to LAK cells and performance in cold target inhibition assays.
Haridas V; Saxena RK
Cell Immunol; 1995 Apr; 161(2):256-61. PubMed ID: 7697736
[TBL] [Abstract][Full Text] [Related]
19. Lymphokine-activated killer cells can kill target cells not only by early killing but also by late killing, and the late killing level against autotumor cell line.
Komatsu F; Ishiguro K
Oncol Res; 2003; 13(4):235-41. PubMed ID: 12659424
[TBL] [Abstract][Full Text] [Related]
20. Transendothelial migration activity of lymphokine-activated killer (LAK) cells.
Kitayama J; Juji T; Atomi Y; Kuroda A; Muto T; Kobayashi M; Mitsui Y; Minami M
J Immunol; 1993 Aug; 151(3):1663-72. PubMed ID: 8335950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
